Latest Regulatory News

Burgundy Diamond Mines reported a mixed Q4 2025 with operational challenges at Ekati and a significant C$115 million loan secured, while trading remains suspended pending regulatory remediation.

1414 Degrees has made significant strides in developing its Aurora Energy Precinct, securing crucial regulatory approvals for its battery storage system and progressing its battery materials and hydrogen technologies.

Echelon Resources reported a slight dip in production but secured long-term gas sales contracts extending to 2034 and plans four new development wells in the Amadeus Basin. The company also reduced its debt by A$7 million, maintaining financial flexibility for growth.

Bridge SaaS Limited reports steady operational progress in its disability services division, highlighted by the launch of a wholly owned NSW subsidiary and solid cash flow results for the December 2025 quarter.

Ovanti Limited advances its U.S. buy now, pay later ambitions through strategic partnerships and a proposed Nasdaq listing valued at US$300 million.

Northern Minerals has made significant strides in developing its Browns Range Heavy Rare Earths Project, securing substantial funding support from US and Australian agencies alongside a $60.5 million capital raise. Exploration success and engineering progress position the company for a Final Investment Decision by late 2026.

Minbos Resources Limited reported a challenging quarter with significant cash outflows but plans a $1 million share purchase plan to bolster its funding position.

Tissue Repair’s December quarter update reveals a cautious path forward for its Phase 3 TR987 trial amid slow patient recruitment, while its TR Pro+ product line gains momentum through a new distributor partnership and upcoming product launches.

Bubs Australia reports a 14% increase in half-year revenue, powered by a 47% jump in US sales, while other regions face challenges. The company remains optimistic about FDA approval and market recovery in H2 FY26.

Recce Pharmaceuticals progresses its Phase 3 diabetic foot infection trial in Indonesia, reports promising preclinical data for inhaled RECCE 327, and secures significant R&D funding and patent protection.

Clime Investment Management appoints John Abernethy as Director of Investments, signalling a renewed focus on investment philosophy and client outcomes. Despite fund closures and regulatory challenges, the company reports improved fund returns and a promising interim profit outlook.

Identitii Limited has secured five new customer contracts worth $250k and seen a four-fold increase in usage of its BNDRY platform, even as its capital raising efforts face delays due to a Takeovers Panel application.